Nanyang Technological University (NTU)'s Associate Professor Zhong Guofu has made a significant contribution to the field of organic chemistry, in particular the study of using small organic molecules as catalysts, in the synthesis process called organocatalysis. Such synthesis process takes place for example, during the production of chiral drugs.

A revolutionary new protein stabilisation technique has been developed by scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) which could lead to 30 per cent more proteins being available as potential targets for drug development - opening up exciting possibilities in drug discovery.

Researchers from Nano-Science Center, University of Copenhagen and National Centre for Scientific Research, France have developed a general method to study membrane proteins. This method can be used to screen several thousand proteins, and it will reduce the way from development to useful drugs substantially.

Nature study reveals long-sought atomic structure of key enzyme and suggests new approach for drug development

Researchers from the European Molecular Biology Laboratory (EMBL) discovered a new way to make use of drugs' unwanted side effects. They developed a computational method that compares how similar the side effects of different drugs are and predicts how likely the drugs act on the same target molecule.

Epix Pharmaceuticals Inc is going to stop further development of its depression drug, which failed to show sufficient effectiveness in a recent mid-stage trial, sending its shares down 32 percent.

A new class of painkillers that block a receptor called TRPV1 may interfere with brain functions such as learning and memory, a new study suggests. The experiments with rat brain found that the TRPV1 receptor regulates a neural mechanism called long-term depression, which is believed to be central to establishing memory pathways in the brain.

There are to date no objective clinical laboratory blood tests for mood disorders. The current reliance on patient self-report of symptom severity and on the clinicians’ impression is a rate limiting step in effective treatment and new drug development.

Guidance from an innovative computational approach could speed up the process and cut down the cost of new drug development, researchers from the University of Chicago Medical Center and Columbia University suggest in a study to be published in the February 2008 issue of Genome Research, available early online.

A new chemical synthesis method based on a catalyst worth many times the price of gold and providing a far more efficient and economical method than traditional ones for designing and manufacturing extremely novel pharmaceutical compounds is described by its University at Buffalo developers in a review article in the current issue of Nature.

Royal Holloway and CABI both bring a combination of individual scientific skills, expertise and resources to the project. When brought together, these offer the opportunity to build a highly focused natural products drug discovery operation that will address the urgent need for bringing new antibiotic compounds to market.

In a major breakthrough for future research and drug development, a team of Los Angeles Biomedical Research Institute (LA BioMed) investigators developed a new, more reliable method for measuring protein synthesis and turnover, processes that are critical to understanding cellular functions.